Carnitine Deficiency  

Carnitine deficiency results from inadequate intake of or inability to metabolize the amino acid carnitine. It can cause a heterogeneous group of disorders. Muscle metabolism is impaired, causing myopathy, hypoglycemia, or cardiomyopathy. Infants typically present with hypoglycemic, hypoketotic encephalopathy. Most often, treatment consists of dietary l-carnitine.

The amino acid carnitine is required for the transport of long-chain fatty acyl coenzyme A (CoA) esters into myocyte mitochondria, where they are oxidized for energy. Carnitine is obtained from foods, particularly animal-based foods, and via endogenous synthesis.

Causes of carnitine deficiency include the following:

  • Inadequate intake (eg, due to fad diets, lack of access, or long-term TPN)
  • Inability to metabolize carnitine due to enzyme deficiencies (eg, carnitine palmitoyltransferase deficiency, methylmalonicaciduria, propionicacidemia, isovalericacidemia)
  • Decreased endogenous synthesis of carnitine due to a severe liver disorder
  • Excess loss of carnitine due to diarrhea, diuresis, or hemodialysis
  • A hereditary disorder in which carnitine leaks from renal tubules
  • Increased requirements for carnitine when ketosis is present or demand for fat oxidation is high (eg, during a critical illness such as sepsis or major burns; after major surgery of the GI tract)
  • Decreased muscle carnitine levels due to mitochondrial impairment (eg, due to use of zidovudine
  • Use of valproate

The deficiency may be generalized (systemic) or may affect mainly muscle (myopathic).


Symptoms and the age at which symptoms appear depend on the cause. Carnitine deficiency may cause muscle necrosis, myoglobinuria, lipid-storage myopathy, hypoglycemia, fatty liver, and hyperammonemia with muscle aches, fatigue, confusion, and cardiomyopathy.



In neonates, carnitine palmitoyltransferase deficiency is diagnosed using mass spectrometry to screen blood. Prenatal diagnosis may be possible using amniotic villous cells. In adults, the definitive diagnosis is based on acylcarnitine levels in serum, urine, and tissues (muscle and liver for systemic deficiency; muscle only for myopathic deficiency).


  • Avoidance of fasting and strenuous exercise
  • Dietary interventions, based on cause

Carnitine deficiency due to inadequate dietary intake, increased requirements, excess losses, decreased synthesis, or (sometimes) enzyme deficiencies can be treated by giving l-carnitine 25 mg/kg po q 6 h.

All patients must avoid fasting and strenuous exercise. Consuming uncooked cornstarch at bedtime prevents early morning hypoglycemia. Some patients require supplementation with medium-chain triglycerides and essential fatty acids (eg, linoleic acid, linolenic acid). Patients with a fatty acid oxidation disorder require a high-carbohydrate, low-fat diet.


Reference: Merck Manual


Copyright © 2017 Global Napi Pharmaceuticals.All rights reserved.
Designed & Developed by | VisionApps Team.